Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BYSI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BYSI

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

BeyondSpring Inc

BYSI
Current price
2.74 USD -0.38 USD (-12.18%)
Last closed 3.11 USD
ISIN KYG108301006
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 125 383 688 USD
Yield for 12 month +10.26 %
1Y
3Y
5Y
10Y
15Y
BYSI
21.11.2021 - 28.11.2021

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.25 USD

P/E ratio

Dividend Yield

Financials BYSI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BYSI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

+1 751 000 USD

Current Quarter

Last Quarter

-1 438 000 USD

Current Year

Last Year

+1 751 000 USD

Current Quarter

Last Quarter

-1 438 000 USD
EBITDA -9 011 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -18.51 %
PEG Ratio
Return On Equity TTM -310.48 %
Wall Street Target Price 1.25 USD
Revenue TTM 1 876 000 USD
Book Value -0.70 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 14.30 %
Dividend Yield
Gross Profit TTM 1 351 000 USD
Earnings per share -0.22 USD
Diluted Eps TTM -0.22 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation BYSI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 10.54
Enterprise Value Revenue 26.53
Price Sales TTM 31.22
Enterprise Value EBITDA 0.047
Price Book MRQ 5.38

Technical indicators BYSI

For 52 weeks

0.98 USD 3.44 USD
50 Day MA 1.78 USD
Shares Short Prior Month 1 842 128
200 Day MA 1.84 USD
Short Ratio 82.18
Shares Short 1 842 748
Short Percent 6.46 %